Cell-penetrating peptides selectively cross the blood-brain barrier in vivo

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Stalmans, Sofie ^a   Bracke, Nathalie ^a   Wynendaele, Evelien ^a   Gevaert, Bert ^a   Peremans, Kathelijne ^a   Burvenich, Christian ^a   Polis, Ingeborgh ^a   De Spiegeleer, Bart ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BOVINE SERUM ALBUMIN; CELL PENETRATING PEPTIDE; RADIOACTIVE IODINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; BLOOD BRAIN BARRIER; BRAIN HOMOGENATE; BRAIN REGION; BRAIN TRANSPORT; CORPUS STRIATUM; ENDOTHELIUM; HIPPOCAMPUS; HYDROPHOBICITY; HYPOTHALAMUS; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY HOMOGENATE; LIVER HOMOGENATE; MOUSE; NONHUMAN; PONS; PROTEIN STABILITY; RADIOACTIVITY; RADIOIODINATION; THALAMUS; TISSUE DISTRIBUTION; TRANSPORT AT THE CELLULAR LEVEL; ANIMAL; BOVINE; BRAIN; CAPILLARY; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; CHEMISTRY; DRUG EFFECTS; INSTITUTE FOR CANCER RESEARCH MOUSE; KIDNEY; LIVER; METABOLISM; REGRESSION ANALYSIS;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARIES; CATTLE; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; CELL-PENETRATING PEPTIDES; IODINE RADIOISOTOPES; KIDNEY; LIVER; MICE; MICE, INBRED ICR; REGRESSION ANALYSIS; SERUM ALBUMIN, BOVINE; TISSUE DISTRIBUTION;

EID: 84948986049     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0139652     Document Type: Article

References (79)

1. Stalmans S, Wynendaele E, Bracke N, Gevaert B, D'Hondt M, Peremans K, et al. Chemical-Functional Diversity in Cell-Penetrating Peptides. PLOS One 2013; 8: e71752. doi: 10.1371/journal.pone.0071752 PMID: 23951237
2. Madani F, Lindberg S, Langel Ü, Futaki S, Gräslund A. Mechanisms of Cellular Uptake of Cell-Penetrating Peptides. J. Biophys. 2011; 2011: 414729. doi: 10.1155/2011/414729 PMID: 21687343
3. Copolovici DM, Langel K, Eriste E, Langel Ü. Cell-Penetrating Peptides: Design, Synthesis, and Applications. ACS Nano 2014; 8: 1972-1994. doi: 10.1021/nn4057269 PMID: 24559246
4. Bechara C, Sagan S. Cell-penetrating peptides: 20 years later, where do we stand? FEBS Lett. 2013; 587: 1693-1702. doi: 10.1016/j.febslet.2013.04.031 PMID: 23669356
5. Milletti F. Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov. Today 2012; 17: 850-860. doi: 10.1016/j.drudis.2012.03.002 PMID: 22465171
6. Lindgren M, Langel Ü. Classes and Prediction of Cell-Penetrating Peptides. In: Langel Ü, editor. Cell-Penetrating Peptides: Methods and Protocols. New York: Human Press; 2011. pp. 3-19.
7. Brugnano J, Ward BC, Panitch A. Cell penetrating peptides can exert biological activity: a review. Biomol. Concepts 2010; 1: 109-116. doi: 10.1515/bmc.2010.016 PMID: 25961990
8. Verdurmen WPR, Brock R. Biological responses towards cationic peptides and drug carriers. Trends Pharmacol. Sci. 2010; 32: 116-124. doi: 10.1016/j.tips.2010.11.005 PMID: 21167610
9. Suhorutsenko J, Eriste E, Copolovici D-M, Langel Ü. Human Protein 53-Derived Cell-Penetrating Peptides. Int. J. Res. Ther. 2012; 18: 291-297.
10. Johansson HJ, El-Andaloussi S, Holm T, Mäe M, Jänes J, Maimets T, et al. Characterization of a Novel Cytotoxic Cell-penetrating Peptide Derived From p14ARF Protein. Mol. Ther. 2008; 16: 115-123. PMID: 17984975
11. Jones S, Holm T, Mäger I, Langel Ü, Howl J. Characterization of Bioactive Cell Penetrating Peptides from Human Cytochrome c: Protein Mimicry and the Development of a Novel Apoptogenic Agent. Chem. Biol. 2010; 17: 735-744. doi: 10.1016/j.chembiol.2010.05.018 PMID: 20659686
12. Sandgren S, Wittrup A, Cheng F, Jönsson M, Eklund E, Busch S, et al. The Human Antimicrobial Peptide LL-37 Transfers Extracellular DNA Plasmid to the Nuclear Compartment of Mammalian Cells via Lipid Rafts and Proteoglycan-dependent Endocytosis. J. Biol. Chem. 2004; 279: 17951-17956. PMID: 14963039
13. Howl J, Matou-Nasri S, West DC, Farquhar M, Slaninova J, Östenson C-G, et al. Bioportide: an emergent concept of bioactive cell-penetrating peptides. Cell. Mol. Life Sci. 2012; 69: 2951-2966. doi:10. 1007/s00018-012-0979-4 PMID: 22527714
14. Taylor BN, Mehta RR, Yamada T, Lekmine F, Christov K, Chakrabarty AM, et al. Noncationic Peptides Obtained From Azurin Preferentially Enter Cancer Cells. Cancer Res. 2009; 69: 537-546. doi: 10.1158/0008-5472.CAN-08-2932 PMID: 19147567
15. Löfgren K, Wahlström A, Lundberg P, Langel Ü, Gräslund A, Bedecs K. Antiprion properties of prion protein-derived cell-penetrating peptides. FASEB J. 2008; 22: 2177-2184. doi: 10.1096/fj.07-099549 PMID: 18296502
16. Li Y, Yokota T, Gama V, Yoshida T, Gomez JA, Ishikawa K, et al. Bax-inhibiting peptide protects cells from polyglutamine toxicity caused by Ku70 acetylation. Cell Death Differ. 2007; 14: 2058-2067. PMID: 17885668
17. Östlund P, Kilk K, Lindgren M, Hällbrink M, Jiang Y, Budihna M, et al. Cell-Penetrating Mimics of Agonist-Activated G-Protein Coupled Receptors. Int. J. Pept. Res. Ther. 2005; 11: 237-247.
18. Jones S, Martel C, Belzacq-Casagrande A-S, Brenner C, Howl J. Mitoparan and target-selective chimeric analogues: Membrane translocation and intracellular redistribution induces mitochondrial apoptosis. Biochim. Biophys. Acta 2008; 1783: 849-863. doi: 10.1016/j.bbamcr.2008.01.009 PMID: 18267123
19. Elmquist A, Lindgren M, Bartfai T, Langel Ü. VE-Cadherin-Derived Cell-Penetrating Peptide, pVEC, with Carrier Functions. Exp. Cell Res. 2001; 269: 237-244. PMID: 11570816
20. Duchardt F, Ruttekolk IR, Verdurmen WPR, Lortat-Jacob H, Bürck J, Hufnagel H, et al. A Cell-penetrating Peptide Derived from Human Lactoferrin with Conformation-dependent Uptake Efficiency. J. Biol. Chem. 2009; 284: 36099-36108. doi: 10.1074/jbc.M109.036426 PMID: 19858187
21. Niarchos DK, Perez SA, Papamichail M. Characterization of a novel cell penetrating peptide derived from Bag-1 protein. Peptides 2006; 27: 2661-2669. PMID: 16808988
22. Doan N-D, Létourneau M, Vaudry D, Doucet N, Folch B, Vaudry H, et al. Design and characterization of novel cell-penetrating peptides from pituitary adenylate cyclase-activating polypeptide. J. Control. Release 2012; 163: 256-265. doi: 10.1016/j.jconrel.2012.08.021 PMID: 22922050
23. Brugnano JL, Chan BK, Seal BL, Panitch A. Cell-penetrating peptides can confer biological function: Regulation of inflammatory cytokines in human monocytes by MK2 inhibitor peptides. J. Control. Release 2011; 155: 128-133. doi: 10.1016/j.jconrel.2011.05.007 PMID: 21600941
24. Nakase I, Hirose H, Tanaka G, Tadokoro A, Kobayashi S, Takeuchi T, et al. Cell-surface Accumulation of Flock House Virus-derived Peptides Leads to Efficient Internalization via Micropinocytosis. Mol. Ther. 2009; 17: 1868-1876. doi: 10.1038/mt.2009.192 PMID: 19707187
25. Manosroi J, Lohcharoenkal W, Götz F, Werner RG, Manosroi W, Manosroi A. Polioviral receptor binding ligand: A novel and safe peptide drug carrier from polioviral capsid. Drug Deliv. 2012; 19: 21-27. doi: 10.3109/10717544.2011.621991 PMID: 22142037
26. Lee J-E, Lim HJ. LDP12, a novel cell-permeable peptide derived from L1 capsid protein of the human papillomavirus. Mol. Biol. Rep. 2012; 39: 1079-1086. doi: 10.1007/s11033-011-0834-y PMID: 21573792
27. Langedijk JPM. Tranlocation activity of C-terminal Domain of Pestivirus Erns and Ribotoxin L3 Loop. J. Biol. Chem. 2002; 277: 5308-5314. PMID: 11673454
28. Lu S, Tager LA, Chitale S, Riley LW. A cell-penetrating peptide derived from mammalian cell uptake protein of Mycobacterium tuberculosis. Anal. Biochem. 2006; 353: 7-14. PMID: 16620748
29. Vivès E, Brodin P, Lebleu B. A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell Nucleus. J. Biol. Chem. 1997; 272: 16010-16017. PMID: 9188504
30. Montrose K, Yang Y, Sun X, Wiles S, Krissansen GW. Xentry, a new class of cell-penetrating peptide uniquely equipped for delivery of drugs. Sci. Rep. 2013; 3: 1661. doi: 10.1038/srep01661 PMID: 23588666
31. Freire JM, Veiga AS, Rego de Figueiredo I, de la Torre BG, Santos NC, Andreu D, et al. Nucleic acid delivery by cell penetrating peptides derived from dengue virus capsid protein: design and mechanism of action. FEBS J. 2014; 281: 191-215. doi: 10.1111/febs.12587 PMID: 24286593
32. Oess S, Hildt E. Novel cell permeable motif derived from the PreS2-domain of hepatitis-B virus surface antigens. Gene Ther. 2000; 7: 750-758. PMID: 10822301
33. Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the bloodbrain barrier. Neurobiol. Dis. 2010; 17: 13-25.
34. Zou L-L, Ma J-L, Wang T, Yang T-B, Liu C-B. Cell-Penetrating Peptide-Mediated Therapeutic Molecule Delivery into the Central Nervous System. Curr. Neuropharmacol. 2013; 1: 197-208.
35. Hervé F, Ghinea N, Scherrmann J-M. CNS Delivery Via Adsorptive Transcytosis. AAPS J. 2008; 10: 455-472. doi: 10.1208/s12248-008-9055-2 PMID: 18726697
36. Rousselle C, Smirnova M, Clair P, Lefauconnier J-M, Chavanieu A, Calas B, et al. Enhanced Delivery of Doxorubicin into the Brain via a Peptide-Vector-Mediated Strategy: Saturation Kinetics and Specificity. J. Pharmacol. Exp. Ther. 2001; 296: 124-131. PMID: 11123372
37. Gjedde A. High-and low-affinity transport of D-glucose from blood to brain. J. Neurochem. 1981; 36: 1463-1471. PMID: 7264642
38. Pan WH, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998; 37: 1553-1561. PMID: 9886678
39. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cerebr. Blood F. Met. 1983; 3: 1-7.
40. Gjedde A. Calculation of cerebral glucose phosphorylation from brain uptake of glucose analogs in vivo: a re-examination. Brain Res. 1982; 257: 237-274. PMID: 7104768
41. Pardridge WM, Eisenberg J, Cefalu WT. Absence of albumin receptor on brain capillaries in vivo or in vitro. Am. J. Physiol. 1985; 249: E264-E267. PMID: 2994489
42. Wong DF, Gjedde A, Wagner HN Jr. Quantification of neuroreceptors in the living human brain. I. Irreversible binding of ligands. J. Cerebr. Blood F. Met. 1986; 6: 137-46.
43. Banks WA, Fasold MB, Kastin AJ. Measurement of Efflux Rates from Brain to Blood. In: Irvine GB, William CH, editors. Methods in Molecular Biology, Neuropeptide Protocols. Totowa: Humana Press Inc.; 1997. pp. 353-360.
44. Banks WA, Jaspan JB, Huang W, Kastin AJ. Transport of Insulin Across the Blood-Brain Barrier: Saturability at Euglycemic Doses of Insulin. Peptides 1997; 18: 1423-1429. PMID: 9392846
45. Stalmans S, Wynendaele E, Bracke N, Knappe D, Hoffmann R, Peremans K, et al. Blood-Brain Barrier Transport of Short Proline-Rich Antimicrobial Peptides. Protein Peptide Lett. 2014; 21: 399-406.
46. Verbeken M, Wynendaele E, Mauchauffée E, Bracke N, Stalmans S, Bojnik E, et al. Blood-brain transfer and antinociception of linear and cyclic N-methyl-guanidine and thiourea-enkephalins. Peptides 2015; 63: 10-21. doi: 10.1016/j.peptides.2014.10.010 PMID: 25451468
47. Novoa A, Van Dorpe S, Wynendaele E, Spetea M, Bracke N, Stalmans S, et al. Variation of the Net Charge, Lipophilicity, and Side Chain Flexibility in Dmt1-DALDA: Effect on Opioid Activity and Biodistribution. J. Med. Chem. 2012; 55: 9549-9561. doi: 10.1021/jm3008079 PMID: 23102273
48. Czihal P, Knappe D, Fritsche S, Zahn M, Berthold N, Piantavigna S, et al. Api88 Is a Novel Antibacterial Designer Peptide To Treat Systemic Infections with Multidrug-Resistant Gram-Negative Pathogens. ACS Chem. Biol. 2012; 7: 1281-1291. doi: 10.1021/cb300063v PMID: 22594381
49. Sarko D, Beijer B, Boy RG, Nothelfer E-M, Leotta K, Eisenhut, et al. The Pharmacokinetics of Cell-Penetrating Peptides. Mol. Pharm. 2010; 7: 2224-2231. doi: 10.1021/mp100223d PMID: 20845937
50. Grunwald J, Rejtar T, Sawant R, Wang Z, Torchilin VP. TAT Peptide and Its Conjugates: Proteolytic Stability. Bioconjugate Chem. 2009; 20: 1531-1537.
51. Elmquist A, Langel Ü. In Vitro Uptake and Stability Study of pVEC and Its All-D analog. Biol. Chem. 2003; 384: 387-393. PMID: 12715889
52. Lindgren ME, Hällbrink MM, Elmquist AM, Langel Ü. Passage of cell-penetrating peptides across a human epithelial cell layer in vitro. Biochem. J. 2004; 377: 69-76. PMID: 12968950
53. Violini S, Sharma V, Prior JL, Dyszlewski M, Worms-Piwnica D. Evidence for a Plasma Membrane-Mediated Permeability Barrier to Tat Basic Domain in Well-Differentiated Epithelial Cells: Lack of Correlation with Heparan Sulfate. Biochemistry-US 2002; 41: 12652-12661.
54. Tréhin R, Krauss U, Beck-Sickinger AG, Merkle HP, Nielsen HM. Cellular Uptake but Low Permeation of Human Calcitonin-Derived Cell-Penetrating Peptides and Tat (47-57) Through Well-Differentiated Epithelial Models. Pharm. Res. 2004; 21: 1248-1256. PMID: 15290867
55. Simon MJ, Kang WH, Gao S, Banta S, Morrisson B III. TAT Is Not Capable of Transcellular Delivery Across an Intact Endothelial Monolayer In Vitro. Ann. Biomed. Eng. 2011; 39: 394-401. doi: 10.1007/s10439-010-0144-x PMID: 20737289
56. Song J, Kai M, Zhang W, Zhang J, Liu L, Zhang B, et al. Cellular uptake of transportan 10 and its analogs in live cells: Selectivity and structure-activity relationship studies. Peptides 2011; 32: 1934-1941. doi: 10.1016/j.peptides.2011.07.018 PMID: 21827806
57. Banks WA, Kastin AJ. Differential Permability of the Blood-Brain Barrier to Two Pancreatic Peptides: Insulin and Amylin. Peptides 1998; 19: 883-889. PMID: 9663454
58. Jay TM, Lucignani G, Crain AM, Jehle J, Sokoloff L. Measurement of Local Cerebral Blood Flow with [14C]Iodoantipyrine in the Mouse. J. Cerebr. Blood F. Met. 1988; 8: 121-129.
59. Kastin AJ, Pan W. Peptide transport across the blood-brain barrier. In: Prokai L, Prokai-Tatrai K, editors. Progress in Drug Research. Basel: Birkhauser Verlag; 2003. pp. 79-100. PMID: 14674609
60. Elmquist A, Hansen M, Langel Ü. Structure-activity relationship study of the cell-penetrating peptide pVEC. BBA-Biomembranes 2006; 1758: 721-729. PMID: 16808894
61. Stalmans S, Gevaert B, Wynendaele E, Nielandt J, De Tré G, Peremans K, et al. Classification of peptides according to their blood-brain barrier influx. Protein Peptide Lett. 2015; 22: 768-775.
62. Drin G, Cottin S, Blanc E, Rees AR, Temsamani J. Studies on the Internalization Mechanism of Cationic Cell-Penetrating Peptides. J. Biol. Chem. 2003; 278: 31192-31201. PMID: 12783857
63. Futaki S, Nakase I, Tadokoro A, Takeuchi T, Jones AT. Arginine-rich peptides and their internalization mechanisms. Biochem. Soc. T. 2007; 35: 784-787.
64. Brock R. The Uptake of Arginine-Rich Cell-Penetrating Peptides: Putting the Puzzle Together. Bioconjugate Chem. 2014; 25: 863-868.
65. Herbig ME, Assi F, Textor M, Merkle HP. The Cell Penetrating Peptides pVEC and W2-pVEC Induce Transformation of Gel Phase Domains in Phospholipid Bilayers without Affecting Their Integrity. Biochemistry-US 2006; 45: 3598-3609.
66. Akdag IO, Ozkirimli E. The Uptake Mechanism of the Cell-Penetrating pVEC Peptide. J. Chem. 2013; 2013: 851915.
67. Padari K, Säälik P, Hansen M, Koppel K, Raid R, Langel Ü, et al. Cell Transduction Pathways of Transportans. Bioconjugate Chem. 2005; 16: 1399-1410.
68. Yandek LE, Pokorny A, Florén A, Knoelke K, Langel Ü, Almeida PFF. Mechanism of the Cell-Penetrating Peptide Transportan 10 Permeation of Lipid Bilayers. Biophys. J. 2007; 92: 2434-2444. PMID: 17218466
69. Islam MZ, Ariyama H, Alam JM, Yamazaki M. Entry of Cell-Penetrating Peptide Transportan 10 into a Single Vesicle by Translocating Across Lipid Membrane and Its Induced Pores. Biochemistry 2014; 53: 386-396. doi: 10.1021/bi401406p PMID: 24397335
70. Éiríksdóttir E, Konate K, Langel Ü, Divita G, Deshayes S. Secondary structure of cell-penetrating peptides controls membrane interaction and insertion. Biochem. Biophys. Acta 2010; 1798: 1119-1128. doi: 10.1016/j.bbamem.2010.03.005 PMID: 20214875
71. Stalmans S, Gevaert B, Verbeke F, D'Hondt M, Bracke N, Wynendaele E, et al. Quality control of cellpenetrating peptides. J. Pharmaceut. Biomed. 2016; 117: 289-297.
72. Vergote V, Baert B, Vandermeulen E, Peremans K, van Bree H, Slegers G, et al. LC-UV/MS characterization and DOE optimization of the iodinated peptide obestatin. J. Pharmaceut. Biomed. 2008; 46: 127-136.
73. Kastin AJ, Akerstrom V, Pan W. Validity of multiple-time regression analysis in measurement of tritiated and iodinated leptin crossing the blood-brain barrier: meaningful controls. Peptides 2001; 22: 2127-2136. PMID: 11786200
74. Gjedde A, Bauer WR, Wong D. Neurokinetics: The dynamics of neurobiology in vivo. New York: Springer US; 2011. doi: 10.1007/978-1-4419-7409-9
75. Triguero D, Buciak J, Pardridge WM. Capillary depletion method for quantification of blood-brain-barrier transport circulating peptides and plasma-proteins. J. Neurochem. 1990; 54: 1882-1888. PMID: 2338547
76. Gutierrez EG, Banks WA, Kastin AJ. Murine tumor-necrosis-factor-alpha is transported from blood to brain in the mouse. J. Neuroimmunol. 1993; 47: 169-176. PMID: 8370768
77. Banks WA, Kastin AJ. Quantifying carrier-mediated transport of peptides from brain to the blood. Method Enzymol. 1989; 168: 652-660.
78. Vergote V, Van Dorpe S, Peremans K, Burvenich C, De Spiegeleer B. In vitro metabolic stability of obestatin: Kinetics and identification of cleavage products. Peptides 2008; 29: 1740-1748. doi:10. 1016/j.peptides.2008.05.018 PMID: 18602197
79. Svenson J, Vergote V, Karstad R, Burvenich C, Svendsen JS, De Spiegeleer B. Metabolic Fate of Lactoferricin-Based Antimicrobial Peptides: Effect of Truncation and Incorporation of Amino Acid Analogs on the In Vitro Metabolic Stability. J. Pharmacol. Exp. Ther. 2010; 332: 1032-1039. doi: 10.1124/jpet. 109.162826 PMID: 19952307